Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Trichinella spiralis gamma-aminobutyric acid (GABA) receptor is a ligand-gated chloride channel belonging to the cys-loop receptor superfamily (Martin, 1997). It plays a fundamental role in the inhibitory neurotransmission of the parasite, specifically mediating muscle relaxation and coordinating locomotor activity (Gao et al., 2023). These receptors are primarily localized at the neuromuscular junctions of the nematode, where GABA binding triggers an influx of chloride ions, leading to membrane hyperpolarization (Bamber et al., 1999). In the context of disease, Trichinella spiralis is the causative agent of trichinellosis, and its GABA receptors are critical targets for anthelmintic intervention (NCBI, 2022). Anthelmintic agents such as piperazine function as agonists at these receptors, inducing flaccid paralysis in the worm to facilitate its clearance from the host intestinal tract (PubChem, 2024). Macrocyclic lactones like ivermectin may also modulate these channels, although their primary affinity is often for glutamate-gated chloride channels (Raymond and Sattelle, 2002). The structural differences between nematode GABA receptor subunits, such as the UNC-49 complex, and mammalian GABA-A receptors provide a basis for selective toxicity, although potential cross-reactivity remains a safety consideration (Bamber et al., 1999). Research into these receptors is ongoing to overcome challenges such as drug resistance and to identify novel binding sites for next-generation antiparasitic drugs (Gao et al., 2023).
Agonism or positive allosteric modulation of GABA-gated chloride channels, leading to chloride ion influx, hyperpolarization of neuromuscular membranes, and flaccid paralysis of the parasite (Martin, 1997; PubChem, 2024).
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Trichinella spiralis gamma-aminobutyric acid receptor (Ts-GABAR).